The list price for Wegovy — Novo Nordisk's brand-name semaglutide 2.4 mg — is approximately $1,349 per month without insurance coverage as of early 2026. For most Americans paying out of pocket, that number ends the conversation before it begins. But it does not represent the full picture of what is available.
The STEP 1 trial, published in the New England Journal of Medicine in 2021, enrolled 1,961 adults with obesity and found once-weekly semaglutide 2.4 mg produced a mean weight loss of 14.9% over 68 weeks, versus 2.4% with placebo (p<0.001).1 These results represent the strongest outcomes data ever generated for obesity pharmacotherapy. The access problem is not clinical — it is economic.
Clinical bottom line
The cheapest safe GLP-1 option in 2026 starts around $149/month through physician-supervised telehealth. Brand-name options remain $900–$1,349/month without insurance — but insurance concierge services can dramatically reduce that for eligible patients.
How GLP-1 Medications Work — and Why Cost Matters
GLP-1 receptor agonists act on hypothalamic satiety centers and slow gastric emptying, producing sustained reductions in appetite and caloric intake. Semaglutide — the active ingredient in Wegovy and Ozempic — has a half-life of approximately 165 to 184 hours, enabling once-weekly dosing.
The STEP 4 trial demonstrated that patients who discontinued semaglutide after 20 weeks of treatment regained approximately two-thirds of the weight lost over the following 48 weeks.2 This means GLP-1 therapy functions more like antihypertensive medication than a time-limited intervention — effective while maintained, with return of the underlying condition upon cessation. Cost sustainability matters enormously for long-term outcomes.
Find a GLP-1 option matched to your state and budget in 60 seconds.
Get My Match →Current Pricing Tiers — Verified April 2026
Monthly cost comparison — physician-supervised GLP-1 programs
| Provider | Starting Price | Included | Medication |
|---|---|---|---|
| Noom Med | From $149/month | GLP-1 access, behavioral coaching, physician oversight | GLP-1 + behavioral program |
| Fridays Health | From $199/month | Physician evaluation, coaching, no hidden fees | Compounded or brand-name |
| Hims & Hers | From $199/month | Physician oversight, 24/7 care team (multi-month) | Compounded semaglutide (46 states) |
| Ro Body | From $294/month | Membership + labs + RN coaching + insurance concierge | Brand-name preferred |
| Wegovy (list) | ~$1,349/month | FDA-approved 2.4 mg from Novo Nordisk | FDA-approved brand-name |
The Insurance Factor — Most Overlooked Cost Lever
For patients with commercial insurance, the single most important variable is prior authorization for brand-name medications. When approved, copays for Wegovy or Zepbound can drop to $25–$50/month. The SELECT trial — enrolling 17,604 patients — found semaglutide 2.4 mg reduced major cardiovascular events by 20% over 40 months in high-risk patients.3 For patients with cardiovascular disease, the clinical case for brand-name access is compelling.
Platforms like Ro Body include an insurance concierge that handles prior authorization and appeals. For insured patients, this service alone can represent thousands of dollars in annual savings versus defaulting to cash-pay compounded programs.
What to Verify Before Enrolling in Any Program
- Physician licensure: A board-certified physician or NP licensed in your state must make the prescribing decision
- Pharmacy credentials: Medications must be dispensed from a licensed 503A, 503B, or retail pharmacy
- Dose escalation: Legitimate programs start at 0.25 mg and escalate over 16–20 weeks
- No pre-approval guarantees: Any platform that guarantees approval before clinical review is a red flag
- Ongoing monitoring: GLP-1 therapy requires clinical follow-up — not just a one-time prescription